Center for Regenerative Medicine
E-MAIL : KONSTEV@BK.RU

Cancer Treatment

Despite decades of research, spent tens of billions of dollars, cancer remains one of the main killers. This disease has a frightening ability to withstand the defenses of the body and evade medical interventions. Unfortunately, effective methods of treating cancer are still absent. For reasons of mortality in developed countries, cancer ranked second and the number of victims continues to grow steadily.

Often one can hear about alternative treatment of cancer. As a rule, this phrase makes sense that this is the most diverse methods of treatment, often completely inadequate, the effectiveness and safety of which has not been proven scientifically. And like this treatment from the field at best fantasies, and on this you can put a point. But, unfortunately, with common malignant tumors there are generally no effective, safe, painless, or proven ways to save cancer patients. In such cases, oncologists can only prescribe chemotherapy that inhibits tumor growth. Then palliative treatment in hospice, thereby facilitating and stretching the process of dying.

But if the patient is still strong and very solvent, then there are possible not standard treatment options: unusually to operate, prescribe targeted drugs or try to prolong life with the newest chemotherapy drugs. In this case, since personalized medicine is just starting to emerge, none of the doctors can guarantee the patient that expensive chemotherapy will not kill him instead of treatment, or the targeted drug will not cause the appearance of new types of tumors.

American scientists believe that the real effectiveness of experimental cancer treatment varies from 11 to 27%. This begs the conclusion that patients at the last stage of the disease should have greater access to information about experimental treatment programs. Patients and their relatives have the right to know what their real chances are with a particular treatment strategy. Scientists believe that the involvement of cancer patients even at the first stages of clinical research can be very useful for them. Even the search for a way out means continuing the fight against the disease. And if a person does not give up, then he maintains a higher level of quality of life.

Alternative cancer treatment is permissible only at the stage of malignant tumor generalization, when known standard methods can no longer be effective. The choice of an alternative way of fighting for the patient’s life should be only in the case of the doomed patient and the lack of probability of rescue by standard oncological methods of treatment.

Specialists of our center are exploring and developing biotherapeutic strategies for the treatment of a widespread oncological process.

One of the first successful approaches to cancer biotherapy is associated with the use of the human placenta. V.Govallo made a great contribution to the rationale for the anticancer effectiveness of preparations based on the placenta. For more than twenty years of his studies, Professor Immunologist, Doctor of Medical Sciences, Head of the Laboratory of Clinical Immunology, CITO them. NNPriorova VIGovallo was able to demonstrate a pronounced antitumor effect, obtained in a special way of placenta extracts in 100 patients with common malignant neoplasms, considered incurable in modern oncology. This way of treating cancer in the seventies of the last century, he was called immunoembryotherapy (IET) or biotherapy. Govallo injected the extract to patients subcutaneously once every 2-3 months for more than a year, and then as necessary. Sometimes the first reaction was mild fever, chills, lethargy. As a rule, after the injection, the tumor decreased, and the patients’ condition improved markedly. Govallo believed that the earlier treatment was initiated and the less accumulated malignant elements in the body, the better the results of cancer biotherapy. The results of his research on oncology professor outlined in the book «Immunology of pregnancy and cancer, which was published in the United States in 1993.

The merit of VI Gavallo is that he perfected the method of preparation and drew attention to an important analogy between the development of the fetus and the tumor, observing the immunological processes in spontaneous abortions. According to his theory, tumor cells suppress tumor-inhibiting factors produced by the immune system of cancer patients, similar to embryos, which also, by secreting inhibitors, overcome maternal immunity. Govallo believed that the introduction of the placenta extract leads to the destruction of the malignant neoplasm protection system from the immune response of the host tumor. If the organism and the immune system of the cancer patient are not damaged by radiation and chemotherapy methods, there is a pronounced response — induced regression (disappearance) of the malignant tumor. The level of scientific knowledge in immunology at that time did not allow Govallo to explain exhaustively the mechanism of the antitumor effect of the extract. It is important to observe that no malignant tumors are present for at least 8 years or more after the effective course of bioembryotherapy. VI Govallo recommended using his method of biotherapy in the first place «… after surgical removal of the tumor to prevent the occurrence of recurrence or metastases or even if they are present.»

Features bilambrioterapii cancer with extracts of the placenta:

The introduction of the placenta extract in case of cancer is carried out subcutaneously at a certain frequency (from 1 time in 2-3 months to 1 time per week) for at least a year, then as necessary.

The introduction of the drug does not cause any serious complications and unpleasant sensations, except for mild fever, chills and lethargy, which last for 1-2 days.

The use of bioembriotherapy improves the health of patients, increases overall resistance and does not require hospitalization.

The safety and efficacy of bioembryotherapy has been traced for 25 years.

The problem of cancer and the organization of its adequate treatment are currently one of the main integrated programs of modern medicine. Malignant neoplasm is a common disease of the body. In connection with this, a new concept of «multifunctional medicines» is being created, in which the limiting selectivity is opposed by the breadth of the pharmacological action, the ability of the drug substance to interact with several targets. In modern conditions, the creation of such drugs requires a systematic approach to any pathological process. This approach to treatment is laid in new scientific disciplines, such as system biology and network pharmacology.

Undoubtedly, the placenta extract is an example of a «multifunctional medicine». We absolutely support the opinion of our American colleagues: with the new advances in the molecular and cellular immunology of cancer, the model introduced by V. I. Govallo can provide an important strategic approach to cancer immunotherapy (Dr. A. Harandi.) Department of Medicine, St. Luke’s-Roosevelt Hospital, Columbia University College of Physicians & Surgeons (USA).

Our center investigates a number of phenomena and effects (spontaneous regression of a malignant tumor, graft-versus-tumor reaction, «concomitant» immunity, tumor immunodeficiency disruption, Hammond and Lentz effects and several others), in the biology of these phenomena, the ways of effective etiopathogenetic treatment of malignant neoplasms are hidden. Our attention was attracted by a unique method of treating cancer with the help of an autologous immunomodulator (AMI), which we considered as a prototype of the research of our Center. The immunomodulator was proposed by the leading scientific employee of the Institute of Immunology of the Ministry of Health of the Russian Federation, Doctor of Medicine Vladimir Ivanovich Novikov.

He, along with colleagues, identified a factor secreted by the cells of the lymph nodes at the earliest stages of the development of immune responses (AMI). The factor has antigen-specific properties and exercises control over the work of the central body of immunity-bone marrow. The phenomenon of production of a mediator, which has a pronounced effect on immunogenesis, is found, regardless of the nature of the antigen. Simultaneous introduction of the factor with antigens of tumor cells leads to a 10-fold increase in humoral and cellular immune responses. Important: «The introduction of tumor antigens with a mediator increased the effect of destruction of tumor cells 6-10 times.» According to the authors, the mechanism of action of AMI is not associated with a direct destructive effect on tumor cells, but is due to the activation of killer defense mechanisms. The technology of preparation, in fact, has similarities to the method of Govallo. AMI in combined treatment of cancer of malignant tumors doubles the efficiency of treatment, increasing the 5-year survival rate for some types of tumors from 15-30 to 60%.

Important properties of the autologous immunomodulator (AMI): 1) absence of toxic effects; 2) has no contraindications and side effects; 3) increases the number of immunocytes in the blood; 4) reduces the indicator of oncomarkers.

Investigating the mechanisms of the antitumor effect of the placenta extract, we found an analogy. In the immunologically privileged area, a so-called disruption of tolerance is possible. This change in privilege can occur in relation to spermatozoa, blastocysts and fetuses. This phenomenon of frustration arises either on the basis of hormonal disorders, manifested first of all by an imbalance of the ratio of hormones, or due to viral and bacterial infections, activating the reactions of local and systemic immunity, including those involving T-lymphocyte helper type 1. Most often, these processes occur in parallel. In this case, the immune system, to a greater extent with the help of a nonspecific component, destroys all cells in a privileged area. With regard to pregnancy, disruption of tolerance leads to the death of the fetus. It turned out that bioembriotherapy initiates a similar mechanism for the loss of malignant neoplasm of the defense system against the immune response of the host tumor, but it requires a nonspecific activator to trigger it. Such an immunological phenomenon was discovered earlier, it has its own name (the phenomenon of a shot was on the spot) and until our research had no practical significance in oncology.

The staff of the center, based on the work of VI Govallo and VI Novikov, modified the bioembriotherapy method, performed a number of experiments on cell cultures of malignant tumors in the presence of serum and immunocytes of the tumor host, as well as experimental studies in animals with transplanted tumors and confirmed the modification efficiency.

We have developed a strategy for the creation of a new biopreparation that has a predictable pronounced antitumor activity in prevalent malignant tumors, based on the mutually reinforcing effect of the two components:

1) inducer of regression of malignant tumors;

2) an activator of an antitumor reaction of local and systemic immunity.

The use of the biopreparation in the treatment of metastatic cancer demonstrates the effect of reversion of a part of the tumor metastases against the background of the gradual destruction (regression) of the primary focus of malignant neoplasm in the host tumor.

As a rule, all over the world, bio-embryotherapy is resorted to after unsuccessful attempts to keep the standard arsenal of cancer treatment methods progressing proliferation and spread of the malignant tumor. And then the treating doctors-oncologists honestly warn patients about the impossibility of curing the patient. Positive results are achieved with bioembryotherapy often, including in the most difficult cases. However, unfortunately, the methods of biotherapy, prolonging life, improving health and eliminating pain syndrome, are not always able to cure common cancer. We are working on strategies for improving the methods of biotherapy, taking into account the biological characteristics of tumors and the organism of the diseased.

Biotherapy is most effective for the treatment of cancer in the following forms of common malignant neoplasms:

Melanoma

Mammary cancer

Cancer of the lung (of different histological structure)

Nasopharyngeal carcinoma

Chondrosarcoma

Adenocarcinoma of the rectum

Synovial sarcoma

Cancer of the Fallopian tubes

Ovarian carcinoma

Sigmoid cancer

Stomach cancer

Prostate cancer

Uterine cancer

Cancer of the bladder

Salivary gland cancer

Bertaline gland cancer

For a preliminary decision on the prospects of treating your disease, it is not necessary to come to the clinic personally. Send an extract from the medical history and all analyzes to the e-mail address konstev@bk.ru or through the Record form on our website. Doctors will hold a consultation and decide on the expediency of your visit.

Яндекс.Метрика